{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T05:11:29Z","timestamp":1794719489547,"version":"4.9.1"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"DOI":"10.1186\/s13048-026-02115-9","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T07:35:21Z","timestamp":1777102521000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Chemoresistance in gynecologic cancers: mechanistic insights and emerging platforms to overcome drug failure"],"prefix":"10.1186","volume":"19","author":[{"given":"Pankaj","family":"Garg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Salgia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6415-8160","authenticated-orcid":false,"given":"Sharad S.","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"key":"2115_CR1","doi-asserted-by":"publisher","first-page":"04155","DOI":"10.7189\/jogh.14.04155","volume":"14","author":"B Zhu","year":"2024","unstructured":"Zhu B, Gu H, Mao Z, Beeraka NM, Zhao X, Anand MP, et al. Global burden of gynaecological cancers in 2022 and projections to 2050. J Glob Health. 2024;14:04155. https:\/\/doi.org\/10.7189\/jogh.14.04155.","journal-title":"J Glob Health"},{"issue":"3","key":"2115_CR2","doi-asserted-by":"publisher","first-page":"e265","DOI":"10.1002\/mco2.265","volume":"4","author":"ZN Lei","year":"2023","unstructured":"Lei ZN, Tian Q, Teng QX, Wurpel JND, Zeng L, Pan Y, et al. Understanding and targeting resistance mechanisms in cancer. MedComm. 2023;4(3):e265. https:\/\/doi.org\/10.1002\/mco2.265.","journal-title":"MedComm"},{"issue":"6","key":"2115_CR3","doi-asserted-by":"publisher","first-page":"821","DOI":"10.2217\/whe.10.60","volume":"6","author":"S Moulder","year":"2010","unstructured":"Moulder S. Intrinsic resistance to chemotherapy in breast cancer. Womens Health. 2010;6(6):821\u201330. https:\/\/doi.org\/10.2217\/whe.10.60.","journal-title":"Womens Health"},{"issue":"42","key":"2115_CR4","doi-asserted-by":"publisher","first-page":"eabp9530","DOI":"10.1126\/sciadv.abp9530","volume":"9","author":"R Uceda-Castro","year":"2023","unstructured":"Uceda-Castro R, Margarido AS, Song JY, et al. BCRP drives intrinsic chemoresistance in chemotherapy-na\u00efve breast cancer brain metastasis. Sci Adv. 2023;9(42):eabp9530. https:\/\/doi.org\/10.1126\/sciadv.abp9530.","journal-title":"Sci Adv"},{"issue":"17","key":"2115_CR5","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.3390\/cancers17172938","volume":"17","author":"K Kannan","year":"2025","unstructured":"Kannan K, Srinivasan A, Kannan A, Ali N. The underlying mechanisms and emerging strategies to overcome resistance in breast cancer. Cancers. 2025;17(17):2938. https:\/\/doi.org\/10.3390\/cancers17172938.","journal-title":"Cancers"},{"issue":"4","key":"2115_CR6","doi-asserted-by":"publisher","first-page":"100996","DOI":"10.1016\/j.currproblcancer.2023.100996","volume":"47","author":"JC Marcolin","year":"2023","unstructured":"Marcolin JC, Lichtenfels M, da Silva CA, de Farias CB. Gynecologic and breast cancers: what\u2019s new in chemoresistance and chemosensitivity tests? Curr Probl Cancer. 2023;47(4):100996. https:\/\/doi.org\/10.1016\/j.currproblcancer.2023.100996.","journal-title":"Curr Probl Cancer"},{"issue":"8","key":"2115_CR7","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.3390\/ph18081086","volume":"18","author":"MM Fallatah","year":"2025","unstructured":"Fallatah MM, Alradwan I, Alfayez N, Aodah AH, Alkhrayef M, Majrashi M, et al. Nanoparticles for cancer immunotherapy: innovations and challenges. Pharmaceuticals Basel. 2025;18(8):1086. https:\/\/doi.org\/10.3390\/ph18081086.","journal-title":"Pharmaceuticals Basel"},{"key":"2115_CR8","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41698-025-00886-w","volume":"9","author":"XH Liu","year":"2025","unstructured":"Liu XH, Wang GR, Zhong NN, et al. Multi-omics in immunotherapy research for HNSCC: present situation and future perspectives. npj Precis Onc. 2025;9:93. https:\/\/doi.org\/10.1038\/s41698-025-00886-w.","journal-title":"npj Precis Onc"},{"issue":"4","key":"2115_CR9","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","volume":"10","author":"U Anand","year":"2022","unstructured":"Anand U, Dey A, Chandel AKS, Sanyal R, Mishra A, Pandey DK, et al. Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis. 2022;10(4):1367\u2013401. https:\/\/doi.org\/10.1016\/j.gendis.2022.02.007.","journal-title":"Genes Dis"},{"key":"2115_CR10","doi-asserted-by":"publisher","first-page":"854730","DOI":"10.3389\/fimmu.2022.854730","volume":"13","author":"Y Wang","year":"2022","unstructured":"Wang Y, Duan M, Peng Z, Fan R, He Y, Zhang H, et al. Advances of DNA damage repair-related drugs and combination with immunotherapy in tumor treatment. Front Immunol. 2022;13:854730. https:\/\/doi.org\/10.3389\/fimmu.2022.854730.","journal-title":"Front Immunol"},{"key":"2115_CR11","doi-asserted-by":"publisher","first-page":"304","DOI":"10.20517\/cdr.2021.147","volume":"5","author":"M Ortiz","year":"2022","unstructured":"Ortiz M, Wabel E, Mitchell K, Horibata S. Mechanisms of chemotherapy resistance in ovarian cancer. Cancer Drug Resist. 2022;5:304\u201316. https:\/\/doi.org\/10.20517\/cdr.2021.147.","journal-title":"Cancer Drug Resist"},{"issue":"3","key":"2115_CR12","doi-asserted-by":"publisher","first-page":"544","DOI":"10.3390\/medicina59030544","volume":"59","author":"A Havasi","year":"2023","unstructured":"Havasi A, Cainap SS, Havasi AT, Cainap C. Ovarian cancer-insights into platinum resistance and overcoming it. Medicina (Kaunas). 2023;59(3):544. https:\/\/doi.org\/10.3390\/medicina59030544.","journal-title":"Medicina (Kaunas)"},{"issue":"5","key":"2115_CR13","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.7150\/thno.69424","volume":"12","author":"C Zhang","year":"2022","unstructured":"Zhang C, Xu C, Gao X, Yao Q. Platinum-based drugs for cancer therapy and anti-tumor strategies. Theranostics. 2022;12(5):2115\u201332. https:\/\/doi.org\/10.7150\/thno.69424.","journal-title":"Theranostics"},{"issue":"2","key":"2115_CR14","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3892\/ol.2025.15130","volume":"30","author":"K Alrosan","year":"2025","unstructured":"Alrosan K, Alrosan AZ, Heilat GB, Alrousan AF, Gammoh OS, Alqudah A, et al. Treatment of ovarian cancer: from the past to the new era (review). Oncol Lett. 2025;30(2):384. https:\/\/doi.org\/10.3892\/ol.2025.15130.","journal-title":"Oncol Lett"},{"key":"2115_CR15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1748-717X-1-15","volume":"1","author":"M Candelaria","year":"2006","unstructured":"Candelaria M, Garcia-Arias A, Cetina L, Due\u00f1as-Gonzalez A. Radiosensitizers in cervical cancer. Cisplatin and beyond. Radiat Oncol. 2006;1:15. https:\/\/doi.org\/10.1186\/1748-717X-1-15.","journal-title":"Radiat Oncol"},{"issue":"4","key":"2115_CR16","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","volume":"103","author":"T Okusaka","year":"2010","unstructured":"Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer. 2010;103(4):469\u201374. https:\/\/doi.org\/10.1038\/sj.bjc.6605779.","journal-title":"Br J Cancer"},{"key":"2115_CR17","doi-asserted-by":"publisher","first-page":"101002","DOI":"10.1016\/j.gore.2022.101002","volume":"41","author":"A Knisely","year":"2022","unstructured":"Knisely A, Huang Y, Li Y, Prabhu VS, Wright JD. Adjuvant and first line chemotherapy use for endometrial cancer. Gynecol Oncol Rep. 2022;41:101002. https:\/\/doi.org\/10.1016\/j.gore.2022.101002.","journal-title":"Gynecol Oncol Rep"},{"issue":"1","key":"2115_CR18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.17925\/EE.2013.09.01.18","volume":"9","author":"EM Stringer","year":"2013","unstructured":"Stringer EM, Fleming GF. Hormone therapy plus mTOR inhibitors in the treatment of endometrial carcinoma. Eur Endocrinol. 2013;9(1):18\u201321. https:\/\/doi.org\/10.17925\/EE.2013.09.01.18.","journal-title":"Eur Endocrinol"},{"key":"2115_CR19","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s11033-023-09096-8","volume":"51","author":"A Zafar","year":"2024","unstructured":"Zafar A, Khan MJ, Abu J, et al. Revolutionizing cancer care strategies: immunotherapy, gene therapy, and molecular targeted therapy. Mol Biol Rep. 2024;51:219. https:\/\/doi.org\/10.1007\/s11033-023-09096-8.","journal-title":"Mol Biol Rep"},{"issue":"3","key":"2115_CR20","doi-asserted-by":"publisher","first-page":"4008","DOI":"10.18632\/oncotarget.14021","volume":"8","author":"K Brasseur","year":"2017","unstructured":"Brasseur K, G\u00e9vry N, Asselin E. Chemoresistance and targeted therapies in ovarian and endometrial cancers. Oncotarget. 2017;8(3):4008\u201342. https:\/\/doi.org\/10.18632\/oncotarget.14021.","journal-title":"Oncotarget"},{"issue":"4","key":"2115_CR21","doi-asserted-by":"publisher","first-page":"784","DOI":"10.20517\/cdr.2021.19","volume":"4","author":"J Goebel","year":"2021","unstructured":"Goebel J, Chmielewski J, Hrycyna CA. The roles of the human ATP-binding cassette transporters P-glycoprotein and ABCG2 in multidrug resistance in cancer and at endogenous sites: future opportunities for structure-based drug design of inhibitors. Cancer Drug Resist. 2021;4(4):784\u2013804. https:\/\/doi.org\/10.20517\/cdr.2021.19.","journal-title":"Cancer Drug Resist"},{"issue":"11","key":"2115_CR22","doi-asserted-by":"publisher","first-page":"6550","DOI":"10.21037\/tcr-24-1129","volume":"13","author":"R Chen","year":"2024","unstructured":"Chen R, Yu Y, Liu R, Chen Q. Targeting breast cancer resistance protein (BCRP\/ABCG2) in cancer. Transl Cancer Res. 2024;13(11):6550\u201364. https:\/\/doi.org\/10.21037\/tcr-24-1129.","journal-title":"Transl Cancer Res"},{"issue":"47","key":"2115_CR23","doi-asserted-by":"publisher","first-page":"7369","DOI":"10.1038\/sj.onc.1206940","volume":"22","author":"DM Townsend","year":"2003","unstructured":"Townsend DM, Tew KD. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene. 2003;22(47):7369\u201375. https:\/\/doi.org\/10.1038\/sj.onc.1206940.","journal-title":"Oncogene"},{"issue":"15","key":"2115_CR24","doi-asserted-by":"publisher","first-page":"8423","DOI":"10.3390\/ijms25158423","volume":"25","author":"E Kalinina","year":"2024","unstructured":"Kalinina E. Glutathione-dependent pathways in cancer cells. Int J Mol Sci. 2024;25(15):8423. https:\/\/doi.org\/10.3390\/ijms25158423.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2115_CR25","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/mco2.55","volume":"2","author":"YP Liu","year":"2021","unstructured":"Liu YP, Zheng CC, Huang YN, He ML, Xu WW, Li B. Molecular mechanisms of chemo- and radiotherapy resistance and the potential implications for cancer treatment. MedComm. 2021;2(3):315\u201340. https:\/\/doi.org\/10.1002\/mco2.55.","journal-title":"MedComm"},{"issue":"1","key":"2115_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3390\/cancers11010119","volume":"11","author":"G Damia","year":"2019","unstructured":"Damia G, Broggini M. Platinum resistance in ovarian cancer: role of DNA repair. Cancers. 2019;11(1):119. https:\/\/doi.org\/10.3390\/cancers11010119.","journal-title":"Cancers"},{"issue":"11","key":"2115_CR27","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","volume":"5","author":"PA Konstantinopoulos","year":"2015","unstructured":"Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D\u2019Andrea AD. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov. 2015;5(11):1137\u201354. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0714.","journal-title":"Cancer Discov"},{"issue":"17","key":"2115_CR28","doi-asserted-by":"publisher","first-page":"4363","DOI":"10.3390\/cancers13174363","volume":"13","author":"CM Neophytou","year":"2021","unstructured":"Neophytou CM, Trougakos IP, Erin N, Papageorgis P. Apoptosis deregulation and the development of cancer multi-drug resistance. Cancers. 2021;13(17):4363. https:\/\/doi.org\/10.3390\/cancers13174363.","journal-title":"Cancers"},{"issue":"4","key":"2115_CR29","doi-asserted-by":"publisher","first-page":"127","DOI":"10.33696\/Signaling.1.021","volume":"1","author":"A Dumont","year":"2020","unstructured":"Dumont A, Lohard S, Maillet L, Juin PP, Barill\u00e9-Nion S. NOXA the BCL-2 family member behind the scenes in cancer treatment. J Cell Signal. 2020;1(4):127\u201343. https:\/\/doi.org\/10.33696\/Signaling.1.021.","journal-title":"J Cell Signal"},{"key":"2115_CR30","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3389\/fmolb.2019.00160","volume":"6","author":"E Henke","year":"2020","unstructured":"Henke E, Nandigama R, Erg\u00fcn S. Extracellular matrix in the tumor microenvironment and its impact on cancer therapy. Front Mol Biosci. 2020;6:160. https:\/\/doi.org\/10.3389\/fmolb.2019.00160.","journal-title":"Front Mol Biosci"},{"key":"2115_CR31","doi-asserted-by":"publisher","first-page":"116498","DOI":"10.1016\/j.bcp.2024.116498","volume":"229","author":"P Garg","year":"2024","unstructured":"Garg P, Ramisetty SK, Raghu Subbalakshmi A, Krishna BM, Pareek S, Mohanty A, et al. Gynecological cancer tumor microenvironment: unveiling cellular complexity and therapeutic potential. Biochem Pharmacol. 2024;229:116498. https:\/\/doi.org\/10.1016\/j.bcp.2024.116498.","journal-title":"Biochem Pharmacol"},{"issue":"9","key":"2115_CR32","doi-asserted-by":"publisher","first-page":"e70333","DOI":"10.1002\/mco2.70333","volume":"6","author":"D Srinivasan","year":"2025","unstructured":"Srinivasan D, Balakrishnan R, Chauhan A, Kumar J, Girija DM, Shrestha R, et al. Epithelial-mesenchymal transition in cancer: insights into therapeutic targets and clinical implications. MedComm. 2025;6(9):e70333. https:\/\/doi.org\/10.1002\/mco2.70333.","journal-title":"MedComm"},{"key":"2115_CR33","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3389\/fonc.2017.00145","volume":"7","author":"O Bilyk","year":"2017","unstructured":"Bilyk O, Coatham M, Jewer M, Postovit LM. Epithelial-to-mesenchymal transition in the female reproductive tract: from normal functioning to disease pathology. Front Oncol. 2017;7:145. https:\/\/doi.org\/10.3389\/fonc.2017.00145.","journal-title":"Front Oncol"},{"issue":"3","key":"2115_CR34","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3390\/cancers17030382","volume":"17","author":"M El-Tanani","year":"2025","unstructured":"El-Tanani M, Rabbani SA, Satyam SM, Rangraze IR, Wali AF, El-Tanani Y, et al. Deciphering the role of cancer stem cells: drivers of tumor evolution, therapeutic resistance, and precision medicine strategies. Cancers. 2025;17(3):382. https:\/\/doi.org\/10.3390\/cancers17030382.","journal-title":"Cancers"},{"issue":"2","key":"2115_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/ddc4020015","volume":"4","author":"P Gupta","year":"2025","unstructured":"Gupta P. Epigenetic alterations in cancer: the therapeutic potential of epigenetic drugs in cancer therapy. Drugs Drug Candidates. 2025;4(2):15. https:\/\/doi.org\/10.3390\/ddc4020015.","journal-title":"Drugs Drug Candidates"},{"key":"2115_CR36","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41392-025-02266-z","volume":"10","author":"J Song","year":"2025","unstructured":"Song J, Yang P, Chen C, et al. Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance. Sig Transduct Target Ther. 2025;10:219. https:\/\/doi.org\/10.1038\/s41392-025-02266-z.","journal-title":"Sig Transduct Target Ther"},{"issue":"4","key":"2115_CR37","doi-asserted-by":"publisher","first-page":"822","DOI":"10.3390\/cancers13040822","volume":"13","author":"A Nicolini","year":"2021","unstructured":"Nicolini A, Ferrari P, Biava PM. Exosomes and cell communication: from tumour-derived exosomes and their role in tumour progression to the use of exosomal cargo for cancer treatment. Cancers. 2021;13(4):822. https:\/\/doi.org\/10.3390\/cancers13040822.","journal-title":"Cancers"},{"issue":"9","key":"2115_CR38","doi-asserted-by":"publisher","first-page":"e70941","DOI":"10.1002\/cam4.70941","volume":"14","author":"N Aakel","year":"2025","unstructured":"Aakel N, Mohammed R, Fathima A, Kerzabi R, Abdallah A, Ibrahim WN. Role of exosome in solid cancer progression and its potential therapeutics in cancer treatment. Cancer Med. 2025;14(9):e70941. https:\/\/doi.org\/10.1002\/cam4.70941.","journal-title":"Cancer Med"},{"issue":"1","key":"2115_CR39","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1186\/s12885-022-10406-9","volume":"22","author":"GY Zhang","year":"2022","unstructured":"Zhang GY, Zhang R, Bai P, Li SM, Zhang YY, Chen YR, et al. Concurrent definitive chemoradiation incorporating intensity-modulated radiotherapy followed by adjuvant chemotherapy in high risk locally advanced cervical squamous cancer: a phase II study. BMC Cancer. 2022;22(1):1331. https:\/\/doi.org\/10.1186\/s12885-022-10406-9.","journal-title":"BMC Cancer"},{"key":"2115_CR40","doi-asserted-by":"publisher","first-page":"700407","DOI":"10.3389\/fonc.2021.700407","volume":"11","author":"Y Li","year":"2021","unstructured":"Li Y, Zhao L, Li XF. Targeting hypoxia: hypoxia-activated prodrugs in cancer therapy. Front Oncol. 2021;11:700407. https:\/\/doi.org\/10.3389\/fonc.2021.700407.","journal-title":"Front Oncol"},{"issue":"3","key":"2115_CR41","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jncc.2025.03.002","volume":"5","author":"X Wang","year":"2025","unstructured":"Wang X, Zhou Y, Wang Y, Yang J, Li Z, Liu F, et al. Overcoming cancer treatment resistance: unraveling the role of cancer-associated fibroblasts. J Natl Cancer Cent. 2025;5(3):237\u201351. https:\/\/doi.org\/10.1016\/j.jncc.2025.03.002.","journal-title":"J Natl Cancer Cent"},{"issue":"5","key":"2115_CR42","doi-asserted-by":"publisher","first-page":"e70878","DOI":"10.1002\/hsr2.70878","volume":"8","author":"A Nazir","year":"2025","unstructured":"Nazir A, Nazir A, Afzaal U, Aman S, Sadiq SUR, Akah OZ, et al. Advancements in biomarkers for early detection and risk stratification of cardiovascular diseases-a literature review. Health Sci Rep. 2025;8(5):e70878. https:\/\/doi.org\/10.1002\/hsr2.70878.","journal-title":"Health Sci Rep"},{"issue":"35","key":"2115_CR43","doi-asserted-by":"publisher","first-page":"59950","DOI":"10.18632\/oncotarget.19048","volume":"8","author":"HC Zheng","year":"2017","unstructured":"Zheng HC. The molecular mechanisms of chemoresistance in cancers. Oncotarget. 2017;8(35):59950\u201364. https:\/\/doi.org\/10.18632\/oncotarget.19048.","journal-title":"Oncotarget"},{"issue":"5","key":"2115_CR44","doi-asserted-by":"publisher","first-page":"189396","DOI":"10.1016\/j.bbcan.2025.189396","volume":"1880","author":"P Garg","year":"2025","unstructured":"Garg P, Singhal G, Horne D, Salgia R, Singhal SS. Metabolic reprogramming in breast cancer: pathways driving progression, drug resistance, and emerging therapeutics. Biochim Biophys Acta Rev Cancer. 2025;1880(5):189396. https:\/\/doi.org\/10.1016\/j.bbcan.2025.189396.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"2","key":"2115_CR45","doi-asserted-by":"publisher","first-page":"101801","DOI":"10.1016\/j.gendis.2025.101801","volume":"13","author":"H Li","year":"2025","unstructured":"Li H, Sheng JJ, Zheng SA, Liu PW, Wu N, Zeng WJ, et al. Platinum-resistant ovarian cancer: from mechanisms to treatment strategies. Genes Dis. 2025;13(2):101801. https:\/\/doi.org\/10.1016\/j.gendis.2025.101801.","journal-title":"Genes Dis"},{"issue":"3","key":"2115_CR46","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.3390\/ijms24031973","volume":"24","author":"GA Atallah","year":"2023","unstructured":"Atallah GA, Kampan NC, Chew KT, Mohd Mokhtar N, Md Zin RR, Shafiee MNb, et al. Predicting prognosis and platinum resistance in ovarian cancer: role of immunohistochemistry biomarkers. Int J Mol Sci. 2023;24(3):1973. https:\/\/doi.org\/10.3390\/ijms24031973.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2115_CR47","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.21037\/gs-20-325","volume":"9","author":"S Garzon","year":"2020","unstructured":"Garzon S, Lagan\u00e0 AS, Casarin J, Raffaelli R, Cromi A, Franchi M, et al. Secondary and tertiary ovarian cancer recurrence: what is the best management? Gland Surg. 2020;9(4):1118\u201329. https:\/\/doi.org\/10.21037\/gs-20-325.","journal-title":"Gland Surg"},{"issue":"2","key":"2115_CR48","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3390\/cancers15020376","volume":"15","author":"K Dzobo","year":"2023","unstructured":"Dzobo K, Senthebane DA, Dandara C. The tumor microenvironment in tumorigenesis and therapy resistance revisited. Cancers. 2023;15(2):376. https:\/\/doi.org\/10.3390\/cancers15020376.","journal-title":"Cancers"},{"issue":"3","key":"2115_CR49","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s13577-023-00882-x","volume":"36","author":"B Xing","year":"2023","unstructured":"Xing B, Pu C, Chen Y, Sheng Y, Zhang B, Cui J, et al. Insights into the characteristics of primary radioresistant cervical cancer using single-cell transcriptomics. Hum Cell. 2023;36(3):1135\u201346. https:\/\/doi.org\/10.1007\/s13577-023-00882-x.","journal-title":"Hum Cell"},{"issue":"23","key":"2115_CR50","doi-asserted-by":"publisher","first-page":"5583","DOI":"10.3390\/cancers15235583","volume":"15","author":"V Folliero","year":"2023","unstructured":"Folliero V, Dell\u2019Annunziata F, Chianese A, Morone MV, Mensitieri F, Di Spirito F, et al. Epigenetic and genetic keys to fight HPV-related cancers. Cancers. 2023;15(23):5583. https:\/\/doi.org\/10.3390\/cancers15235583.","journal-title":"Cancers"},{"key":"2115_CR51","doi-asserted-by":"publisher","first-page":"102021","DOI":"10.1016\/j.ctrv.2020.102021","volume":"86","author":"TT Huang","year":"2020","unstructured":"Huang TT, Lampert EJ, Coots C, Lee JM. Targeting the PI3K pathway and DNA damage response as a therapeutic strategy in ovarian cancer. Cancer Treat Rev. 2020;86:102021. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102021.","journal-title":"Cancer Treat Rev"},{"issue":"24","key":"2115_CR52","doi-asserted-by":"publisher","first-page":"6210","DOI":"10.3390\/cancers14246210","volume":"14","author":"M Lv","year":"2022","unstructured":"Lv M, Chen P, Bai M, Huang Y, Li L, Feng Y, et al. Progestin resistance and corresponding management of abnormal endometrial hyperplasia and endometrial carcinoma. Cancers. 2022;14(24):6210. https:\/\/doi.org\/10.3390\/cancers14246210.","journal-title":"Cancers"},{"key":"2115_CR53","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.semcancer.2023.05.002","volume":"93","author":"M Lee-Rueckert","year":"2023","unstructured":"Lee-Rueckert M, Canyelles M, Tondo M, Rotllan N, Kovanen PT, Llorente-Cortes V, et al. Obesity-induced changes in cancer cells and their microenvironment: mechanisms and therapeutic perspectives to manage dysregulated lipid metabolism. Semin Cancer Biol. 2023;93:36\u201351. https:\/\/doi.org\/10.1016\/j.semcancer.2023.05.002.","journal-title":"Semin Cancer Biol"},{"issue":"15","key":"2115_CR54","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.3390\/cancers17152557","volume":"17","author":"S Nagao","year":"2025","unstructured":"Nagao S, Fujikawa A, Imatani R, Tani Y, Matsuoka H, Ida N, et al. The concept of \u201cplatinum sensitivity\u201d in endometrial cancer. Cancers. 2025;17(15):2557. https:\/\/doi.org\/10.3390\/cancers17152557.","journal-title":"Cancers"},{"issue":"10","key":"2115_CR55","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.ccell.2023.09.006","volume":"41","author":"M Zhu","year":"2023","unstructured":"Zhu M, Kim J, Deng Q, Ricciuti B, Alessi JV, Eglenen-Polat B, et al. Loss of p53 and mutational heterogeneity drives immune resistance in an autochthonous mouse lung cancer model with high tumor mutational burden. Cancer Cell. 2023;41(10):1731-1748.e8. https:\/\/doi.org\/10.1016\/j.ccell.2023.09.006.","journal-title":"Cancer Cell"},{"issue":"1","key":"2115_CR56","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s43556-025-00352-w","volume":"6","author":"J Li","year":"2025","unstructured":"Li J, Hu J, Yang Y, Zhang H, Liu Y, Fang Y, et al. Drug resistance in cancer: molecular mechanisms and emerging treatment strategies. Mol Biomed. 2025;6(1):111. https:\/\/doi.org\/10.1186\/s43556-025-00352-w.","journal-title":"Mol Biomed"},{"issue":"13","key":"2115_CR57","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.3390\/cancers16132478","volume":"16","author":"P Garg","year":"2024","unstructured":"Garg P, Malhotra J, Kulkarni P, Horne D, Salgia R, Singhal SS. Emerging therapeutic strategies to overcome drug resistance in cancer cells. Cancers. 2024;16(13):2478. https:\/\/doi.org\/10.3390\/cancers16132478.","journal-title":"Cancers"},{"key":"2115_CR58","doi-asserted-by":"publisher","first-page":"1680838","DOI":"10.3389\/fimmu.2025.1680838","volume":"16","author":"J Park","year":"2025","unstructured":"Park J, Sk\u00e5lhegg BS. Combination of PD-1\/PD-L1 and CTLA-4 inhibitors in the treatment of cancer - a brief update. Front Immunol. 2025;16:1680838. https:\/\/doi.org\/10.3389\/fimmu.2025.1680838.","journal-title":"Front Immunol"},{"issue":"1","key":"2115_CR59","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.gendis.2023.02.014","volume":"11","author":"X Fu","year":"2023","unstructured":"Fu X, Li P, Zhou Q, He R, Wang G, Zhu S, et al. Mechanism of PARP inhibitor resistance and potential overcoming strategies. Genes Dis. 2023;11(1):306\u201320. https:\/\/doi.org\/10.1016\/j.gendis.2023.02.014.","journal-title":"Genes Dis"},{"issue":"1","key":"2115_CR60","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s13046-025-03509-1","volume":"44","author":"C Zhao","year":"2025","unstructured":"Zhao C, Liu Y, Cui Z. Epigenetic regulation in gynecological cancers: a paradigm shift in immunotherapy strategies. J Exp Clin Cancer Res. 2025;44(1):275. https:\/\/doi.org\/10.1186\/s13046-025-03509-1.","journal-title":"J Exp Clin Cancer Res"},{"key":"2115_CR61","doi-asserted-by":"publisher","first-page":"326","DOI":"10.12688\/f1000research.11771.1","volume":"7","author":"S Ma","year":"2018","unstructured":"Ma S, Pradeep S, Hu W, Zhang D, Coleman R, Sood A. The role of tumor microenvironment in resistance to anti-angiogenic therapy. F1000Res. 2018;7:326. https:\/\/doi.org\/10.12688\/f1000research.11771.1.","journal-title":"F1000Res"},{"key":"2115_CR62","doi-asserted-by":"publisher","first-page":"1583992","DOI":"10.3389\/fmolb.2025.1583992","volume":"12","author":"G Schwarz","year":"2025","unstructured":"Schwarz G, Ren X, Xie W, Guo H, Jiang Y, Zhang J. Engineered exosomes: a promising drug delivery platform with therapeutic potential. Front Mol Biosci. 2025;12:1583992. https:\/\/doi.org\/10.3389\/fmolb.2025.1583992.","journal-title":"Front Mol Biosci"},{"issue":"1","key":"2115_CR63","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1186\/s12951-022-01626-z","volume":"20","author":"P Yadav","year":"2022","unstructured":"Yadav P, Ambudkar SV, Rajendra Prasad N. Emerging nanotechnology-based therapeutics to combat multidrug-resistant cancer. J Nanobiotechnol. 2022;20(1):423. https:\/\/doi.org\/10.1186\/s12951-022-01626-z.","journal-title":"J Nanobiotechnol"},{"issue":"27","key":"2115_CR64","doi-asserted-by":"publisher","first-page":"28670","DOI":"10.1021\/acsomega.5c02916","volume":"10","author":"A Muley","year":"2025","unstructured":"Muley A, Navale A, Gupta R, Tekade RK. \u201cNano-paclitaxel\u201d unlocking potential and redefining cancer chemotherapy. ACS Omega. 2025;10(27):28670\u201390. https:\/\/doi.org\/10.1021\/acsomega.5c02916.","journal-title":"ACS Omega"},{"issue":"10","key":"2115_CR65","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.3390\/pharmaceutics16101328","volume":"16","author":"DR Serrano","year":"2024","unstructured":"Serrano DR, Luciano FC, Anaya BJ, Ongoren B, Kara A, Molina G, et al. Artificial intelligence (AI) applications in drug discovery and drug delivery: revolutionizing personalized medicine. Pharmaceutics. 2024;16(10):1328. https:\/\/doi.org\/10.3390\/pharmaceutics16101328.","journal-title":"Pharmaceutics"},{"key":"2115_CR66","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13048-026-01979-1","volume":"19","author":"M Singh","year":"2026","unstructured":"Singh M, Betgeri SN, Kakar SS. Artificial intelligence (AI) and machine learning (ML) in ovarian cancer: transforming detection, treatment, and prevention. J Ovarian Res. 2026;19:91. https:\/\/doi.org\/10.1186\/s13048-026-01979-1.","journal-title":"J Ovarian Res"},{"key":"2115_CR67","doi-asserted-by":"publisher","first-page":"998222","DOI":"10.3389\/fonc.2022.998222","volume":"12","author":"J Liao","year":"2023","unstructured":"Liao J, Li X, Gan Y, Han S, Rong P, Wang W, et al. Artificial intelligence assists precision medicine in cancer treatment. Front Oncol. 2023;12:998222. https:\/\/doi.org\/10.3389\/fonc.2022.998222.","journal-title":"Front Oncol"},{"key":"2115_CR68","doi-asserted-by":"publisher","first-page":"111223","DOI":"10.1016\/j.biopha.2021.111223","volume":"136","author":"ZX Wu","year":"2021","unstructured":"Wu ZX, Mai Q, Yang Y, Wang JQ, Ma H, Zeng L, et al. Overexpression of human ATP-binding cassette transporter ABCG2 contributes to reducing the cytotoxicity of GSK1070916 in cancer cells. Biomed Pharmacother. 2021;136:111223. https:\/\/doi.org\/10.1016\/j.biopha.2021.111223.","journal-title":"Biomed Pharmacother"},{"issue":"1\u20132","key":"2115_CR69","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.ijpharm.2018.08.047","volume":"550","author":"J Huttunen","year":"2018","unstructured":"Huttunen J, Gynther M, Huttunen KM. Targeted efflux transporter inhibitors - a solution to improve poor cellular accumulation of anti-cancer agents. Int J Pharm. 2018;550(1\u20132):278\u201389. https:\/\/doi.org\/10.1016\/j.ijpharm.2018.08.047.","journal-title":"Int J Pharm"},{"issue":"4","key":"2115_CR70","doi-asserted-by":"publisher","first-page":"101482","DOI":"10.1016\/j.gendis.2024.101482","volume":"12","author":"SM Alnasser","year":"2024","unstructured":"Alnasser SM. The role of glutathione S-transferases in human disease pathogenesis and their current inhibitors. Genes Dis. 2024;12(4):101482. https:\/\/doi.org\/10.1016\/j.gendis.2024.101482.","journal-title":"Genes Dis"},{"issue":"1","key":"2115_CR71","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1158\/1535-7163.MCT-10-0699","volume":"10","author":"SS Singhal","year":"2011","unstructured":"Singhal SS, Wickramarachchi D, Yadav S, Singhal J, Leake K, Vatsyayan R, et al. Glutathione-conjugate transport by RLIP76 is required for clathrin-dependent endocytosis and chemical carcinogenesis. Mol Cancer Ther. 2011;10(1):16\u201328. https:\/\/doi.org\/10.1158\/1535-7163.MCT-10-0699.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"2115_CR72","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13048-025-01740-0","volume":"18","author":"BM Krishna","year":"2025","unstructured":"Krishna BM, Garg P, Kulkarni P, Horne D, Salgia R, Singhal SS. Targeting the oncoprotein RLIP as novel therapy for ovarian cancer. J Ovarian Res. 2025;18(1):150. https:\/\/doi.org\/10.1186\/s13048-025-01740-0.","journal-title":"J Ovarian Res"},{"issue":"22","key":"2115_CR73","doi-asserted-by":"publisher","first-page":"12387","DOI":"10.3390\/ijms252212387","volume":"25","author":"S Ju","year":"2024","unstructured":"Ju S, Singh MK, Han S, Ranbhise J, Ha J, Choe W, et al. Oxidative stress and cancer therapy: controlling cancer cells using reactive oxygen species. Int J Mol Sci. 2024;25(22):12387. https:\/\/doi.org\/10.3390\/ijms252212387.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2115_CR74","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.31557\/APJCP.2025.26.6.1931","volume":"26","author":"S Devi","year":"2025","unstructured":"Devi S, Chandrababu R. Impact of olaparib, niraparib, rucaparib therapies on newly diagnosed and relapsed ovarian cancer -systematic review and meta-analysis. Asian Pac J Cancer Prev. 2025;26(6):1931\u201341. https:\/\/doi.org\/10.31557\/APJCP.2025.26.6.1931.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"3","key":"2115_CR75","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.radonc.2017.09.043","volume":"126","author":"Z Qiu","year":"2018","unstructured":"Qiu Z, Oleinick NL, Zhang J. ATR\/CHK1 inhibitors and cancer therapy. Radiother Oncol. 2018;126(3):450\u201364. https:\/\/doi.org\/10.1016\/j.radonc.2017.09.043.","journal-title":"Radiother Oncol"},{"issue":"1","key":"2115_CR76","doi-asserted-by":"publisher","first-page":"e70586","DOI":"10.1002\/ctm2.70586","volume":"16","author":"J Li","year":"2026","unstructured":"Li J, Zhang L, Shang Y, Liu J, Zhao H. Synthetic lethality in cancer therapy: mechanisms, models and clinical translation for overcoming therapeutic resistance. Clin Transl Med. 2026;16(1):e70586. https:\/\/doi.org\/10.1002\/ctm2.70586.","journal-title":"Clin Transl Med"},{"key":"2115_CR77","doi-asserted-by":"publisher","first-page":"576946","DOI":"10.3389\/fcell.2020.576946","volume":"8","author":"G Li","year":"2020","unstructured":"Li G, Tian Y, Zhu WG. The roles of histone deacetylases and their inhibitors in cancer therapy. Front Cell Dev Biol. 2020;8:576946. https:\/\/doi.org\/10.3389\/fcell.2020.576946.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"2115_CR78","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","volume":"141","author":"SV Sharma","year":"2010","unstructured":"Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010;141(1):69\u201380. https:\/\/doi.org\/10.1016\/j.cell.2010.02.027.","journal-title":"Cell"},{"issue":"5","key":"2115_CR79","doi-asserted-by":"publisher","first-page":"680","DOI":"10.4103\/ijmr.IJMR_1160_19","volume":"154","author":"Y Liu","year":"2021","unstructured":"Liu Y, Luo Y, Cai M, Shen P, Li J, Chen H, et al. Anti-angiogenic therapy in ovarian cancer: current situation & prospects. Indian J Med Res. 2021;154(5):680\u201390. https:\/\/doi.org\/10.4103\/ijmr.IJMR_1160_19.","journal-title":"Indian J Med Res"},{"key":"2115_CR80","doi-asserted-by":"publisher","first-page":"105068","DOI":"10.1016\/j.critrevonc.2025.105068","volume":"217","author":"M Rota","year":"2026","unstructured":"Rota M, Torresan I, Palmerio S, Tasselli E, Rossi A, Zivi A, et al. The role of therapeutic cancer vaccines in the modern immunotherapy era: state of the art with recent progress and future challenges. Crit Rev Oncol Hematol. 2026;217:105068. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105068.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11","key":"2115_CR81","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.3390\/cancers15112912","volume":"15","author":"C Sordo-Bahamonde","year":"2023","unstructured":"Sordo-Bahamonde C, Lorenzo-Herrero S, Gonzalez-Rodriguez AP, Mart\u00ednez-P\u00e9rez A, Rodrigo JP, Garc\u00eda-Pedrero JM, et al. Chemo-immunotherapy: a new trend in cancer treatment. Cancers. 2023;15(11):2912. https:\/\/doi.org\/10.3390\/cancers15112912.","journal-title":"Cancers"},{"issue":"6","key":"2115_CR82","doi-asserted-by":"publisher","first-page":"802","DOI":"10.3390\/biom15060802","volume":"15","author":"R Ganpisetti","year":"2025","unstructured":"Ganpisetti R, Giridharan S, Vaskuri GSSJ, Narang N, Basim P, Dokmeci MR, et al. Biological nanocarriers in cancer therapy: cutting edge innovations in precision drug delivery. Biomolecules. 2025;15(6):802. https:\/\/doi.org\/10.3390\/biom15060802.","journal-title":"Biomolecules"},{"issue":"9","key":"2115_CR83","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.3390\/biomedicines9091275","volume":"9","author":"E Bellotti","year":"2021","unstructured":"Bellotti E, Cascone MG, Barbani N, Rossin D, Rastaldo R, Giachino C, et al. Targeting cancer cells overexpressing folate receptors with new terpolymer-based nanocapsules: toward a novel targeted DNA delivery system for cancer therapy. Biomedicines. 2021;9(9):1275. https:\/\/doi.org\/10.3390\/biomedicines9091275.","journal-title":"Biomedicines"},{"key":"2115_CR84","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12943-025-02463-y","volume":"24","author":"Y Yan","year":"2025","unstructured":"Yan Y, Liu S, Wen J, et al. Advances in RNA-based cancer therapeutics: pre-clinical and clinical implications. Mol Cancer. 2025;24:251. https:\/\/doi.org\/10.1186\/s12943-025-02463-y.","journal-title":"Mol Cancer"},{"issue":"1","key":"2115_CR85","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1186\/s12951-025-03827-8","volume":"23","author":"X Qian","year":"2025","unstructured":"Qian X, Yuan Y, Zhang Y, Li M, Wang X, Li W, et al. Synergistic effect study on the co-delivery of paclitaxel and SiRNA targeting STMN1 based on MPDA nanoparticles in the therapy of ovarian cancer. J Nanobiotechnology. 2025;23(1):763. https:\/\/doi.org\/10.1186\/s12951-025-03827-8.","journal-title":"J Nanobiotechnology"},{"key":"2115_CR86","doi-asserted-by":"publisher","first-page":"43","DOI":"10.20517\/cdr.2024.97","volume":"7","author":"W Pan","year":"2024","unstructured":"Pan W, Miao Q, Yin W, Li X, Ye W, Zhang D, et al. The role and clinical applications of exosomes in cancer drug resistance. Cancer Drug Resist. 2024;7:43. https:\/\/doi.org\/10.20517\/cdr.2024.97.","journal-title":"Cancer Drug Resist"},{"key":"2115_CR87","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s43046-025-00289-9","volume":"37","author":"S Sonwane","year":"2025","unstructured":"Sonwane S, Telrandhe U, Chambhare N, et al. Unraveling exosome-mediated cancer therapy resistance: pathways and therapeutic challenges. J Egypt Natl Cancer Inst. 2025;37:30. https:\/\/doi.org\/10.1186\/s43046-025-00289-9.","journal-title":"J Egypt Natl Cancer Inst"},{"key":"2115_CR88","doi-asserted-by":"publisher","first-page":"e202500653","DOI":"10.1002\/cmdc.202500653","volume":"21","author":"K Unnikrishnan","year":"2026","unstructured":"Unnikrishnan K, Mahesh A, Kumar RMR. Therapeutic exosomes for rare cancers: advances and clinical translation. ChemMedChem. 2026;21:e202500653. https:\/\/doi.org\/10.1002\/cmdc.202500653.","journal-title":"ChemMedChem"},{"key":"2115_CR89","doi-asserted-by":"publisher","first-page":"106696","DOI":"10.1016\/j.jddst.2025.10669","volume":"106","author":"WY Rizg","year":"2025","unstructured":"Rizg WY, Alghamdi MA, El Saadany S, Madkhali OA, Nair AK, Rashid MA, et al. Recent advances and future prospects of engineered exosomes as advanced drug and gene delivery systems. J Drug Deliv Sci Technol. 2025;106:106696. https:\/\/doi.org\/10.1016\/j.jddst.2025.10669.","journal-title":"J Drug Deliv Sci Technol"},{"key":"2115_CR90","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1016\/j.csbj.2025.07.043","volume":"27","author":"J Chen","year":"2025","unstructured":"Chen J, Yi Y, Yang C, Ying H, Zhang J, Lin A, et al. Integrative machine learning approach for forecasting lung cancer chemosensitivity: from algorithm to cell line validation. Comput Struct Biotechnol J. 2025;27:3307\u201318. https:\/\/doi.org\/10.1016\/j.csbj.2025.07.043.","journal-title":"Comput Struct Biotechnol J"},{"issue":"1","key":"2115_CR91","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s10238-025-01965-9","volume":"26","author":"CY Hsu","year":"2025","unstructured":"Hsu CY, Askar S, Alshkarchy SS, Nayak PP, Attabi KAL, Khan MA, et al. AI-driven multi-omics integration in precision oncology: bridging the data deluge to clinical decisions. Clin Exp Med. 2025;26(1):29. https:\/\/doi.org\/10.1007\/s10238-025-01965-9.","journal-title":"Clin Exp Med"},{"issue":"17","key":"2115_CR92","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.3390\/cancers17172799","volume":"17","author":"P Garg","year":"2025","unstructured":"Garg P, Krishna M, Kulkarni P, Horne D, Salgia R, Singhal SS. Machine learning models for predicting gynecological cancers: advances, challenges, and future directions. Cancers. 2025;17(17):2799. https:\/\/doi.org\/10.3390\/cancers17172799.","journal-title":"Cancers"},{"key":"2115_CR93","doi-asserted-by":"publisher","first-page":"e00938","DOI":"10.1016\/j.btre.2025.e00938","volume":"48","author":"P Sibilio","year":"2025","unstructured":"Sibilio P, De Smaele E, Paci P, Conte F. Integrating multi-omics data: methods and applications in human complex diseases. Biotechnol Rep (Amst). 2025;48:e00938. https:\/\/doi.org\/10.1016\/j.btre.2025.e00938.","journal-title":"Biotechnol Rep (Amst)"},{"issue":"1","key":"2115_CR94","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s41392-024-02021-w","volume":"9","author":"L Ma","year":"2024","unstructured":"Ma L, Guo H, Zhao Y, Liu Z, Wang C, Bu J, et al. Liquid biopsy in cancer current: status, challenges and future prospects. Signal Transduct Target Ther. 2024;9(1):336. https:\/\/doi.org\/10.1038\/s41392-024-02021-w.","journal-title":"Signal Transduct Target Ther"},{"issue":"23","key":"2115_CR95","doi-asserted-by":"publisher","first-page":"14937","DOI":"10.3390\/ijms232314937","volume":"23","author":"E Kudelova","year":"2022","unstructured":"Kudelova E, Smolar M, Holubekova V, Hornakova A, Dvorska D, Lucansky V, et al. Genetic heterogeneity, tumor microenvironment and immunotherapy in triple-negative breast cancer. Int J Mol Sci. 2022;23(23):14937. https:\/\/doi.org\/10.3390\/ijms232314937.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"2115_CR96","doi-asserted-by":"publisher","first-page":"e020170","DOI":"10.1136\/bmjgh-2025-020170","volume":"10","author":"LM Muhe","year":"2025","unstructured":"Muhe LM, Anderson SG, Brown P, Campbell M, Clement Y, Cohall D, et al. A call to strengthen clinical trials capacity in resource-limited settings. BMJ Glob Health. 2025;10(8):e020170. https:\/\/doi.org\/10.1136\/bmjgh-2025-020170.","journal-title":"BMJ Glob Health"},{"issue":"1","key":"2115_CR97","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13073-022-01102-1","volume":"14","author":"E Fountzilas","year":"2022","unstructured":"Fountzilas E, Tsimberidou AM, Vo HH, Kurzrock R. Clinical trial design in the era of precision medicine. Genome Med. 2022;14(1):101. https:\/\/doi.org\/10.1186\/s13073-022-01102-1.","journal-title":"Genome Med"},{"issue":"13","key":"2115_CR98","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.3390\/cancers16132479","volume":"16","author":"S Musa","year":"2024","unstructured":"Musa S, Amara N, Selawi A, Wang J, Marchini C, Agbarya A, et al. Overcoming chemoresistance in cancer: the promise of Crizotinib. Cancers. 2024;16(13):2479. https:\/\/doi.org\/10.3390\/cancers16132479.","journal-title":"Cancers"},{"issue":"9","key":"2115_CR99","doi-asserted-by":"publisher","first-page":"786","DOI":"10.3390\/cells13090786","volume":"13","author":"M Nunes","year":"2024","unstructured":"Nunes M, Bartosch C, Abreu MH, Richardson A, Almeida R, Ricardo S. Deciphering the molecular mechanisms behind drug resistance in ovarian cancer to unlock efficient treatment options. Cells. 2024;13(9):786. https:\/\/doi.org\/10.3390\/cells13090786.","journal-title":"Cells"},{"issue":"2","key":"2115_CR100","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.cpt.2025.07.001","volume":"4","author":"VK Dhiman","year":"2025","unstructured":"Dhiman VK, Kumari M, Singh D. Chemoresistance: the hidden barrier in cancer treatment. Cancer Pathog Ther. 2025;4(2):98\u2013109. https:\/\/doi.org\/10.1016\/j.cpt.2025.07.001.","journal-title":"Cancer Pathog Ther"},{"issue":"17","key":"2115_CR101","doi-asserted-by":"publisher","first-page":"9451","DOI":"10.3390\/ijms22179451","volume":"22","author":"A Ramos","year":"2021","unstructured":"Ramos A, Sadeghi S, Tabatabaeian H. Battling chemoresistance in cancer: root causes and strategies to uproot them. Int J Mol Sci. 2021;22(17):9451. https:\/\/doi.org\/10.3390\/ijms22179451.","journal-title":"Int J Mol Sci"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-026-02115-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-026-02115-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-026-02115-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T02:34:55Z","timestamp":1777257295000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13048-026-02115-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":101,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2115"],"URL":"https:\/\/doi.org\/10.1186\/s13048-026-02115-9","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"31 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"162"}}